文献速递慢阻肺

三重疗法对慢阻肺心血管及严重心肺事件的影响:ETHOS试验事后分析

Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis of a Randomized, Double-Blind, Phase 3 Clinical Trial (ETHOS).
PubMed 文献 · Am J Respir Crit Care Med · 2025-01-01

ETHOS试验事后分析评估布地奈德/格隆溴铵/福莫特罗(BGF)320/18/9.6 μg对慢阻肺患者心血管及严重心肺事件的影响。与格隆溴铵/福莫特罗(GFF)相比,BGF 320降低首次心血管特殊关注不良事件、心脏不良事件及严重心肺事件复合终点的风险。

要点

  • BGF 320较GFF降低心血管特殊关注不良事件风险(HR 0.63)。
  • BGF 320较GFF降低心脏不良事件风险(HR 0.60)。
  • BGF 320较GFF降低严重心肺事件复合终点风险(HR 0.80)。

核心结论

  • 在中重度至极重度慢阻肺患者中,BGF 320较GFF对心血管终点和严重心肺事件具有获益。

研究设计与样本

  • ETHOS试验(NCT02465567)是一项52周、随机、双盲、III期临床试验的事后分析。
  • 患者随机接受每日两次BGF 320、BGF 160、BFF 320或GFF 18/9.6 μg治疗。

主要发现

  • BGF 320较GFF降低首次心血管特殊关注不良事件风险(HR 0.63,95%CI 0.48-0.82)。
  • BGF 320较GFF降低首次心脏不良事件风险(HR 0.60,95%CI 0.48-0.76)。
  • BGF 320较GFF降低首次严重心肺事件复合终点风险(HR 0.80,95%CI 0.67-0.95)。

临床怎么用

  • 对于有加重史的中重度至极重度慢阻肺患者,选择含ICS的三联疗法可能有助于降低心血管及严重心肺事件风险。

局限性

  • 心血管和严重心肺终点为事后分析,需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Chronic obstructive pulmonary disease (COPD) is associated with an increased risk of cardiovascular and cardiopulmonary events. In the phase III, 52-week ETHOS trial (NCT02465567), triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF) reduced rates of moderate/severe exacerbations and all-cause mortality compared with dual therapy with glycopyrrolate/formoterol fumarate (GFF) or budesonide/formoterol fumarate (BFF). However, the effect of BGF on cardiovascular events versus GFF remains unevaluated. Furthermore, the effect of BGF on time to first severe exacerbation has not been reported. Objectives: To assess the effects of BGF 320/18/9.6 μg (BGF 320) and other inhaled corticosteroid-containing arms on cardiovascular and severe cardiopulmonary endpoints versus GFF in patients with COPD from the ETHOS trial. Methods: Patients with moderate to very severe COPD and a history of exacerbations were randomized to twice-daily BGF 320, BGF 160/18/9.6 μg, BFF 320/9.6 μg, or GFF 18/9.6 μg (GFF). Time to first severe COPD exacerbation was a prespecified endpoint; post hoc cardiovascular and severe cardiopulmonary endpoints included time to first major adverse cardiac event, time to first cardiovascular adverse event (AE) of special interest, time to first cardiac AE, and time to the composite endpoint of first severe cardiopulmonary event. Measurements and Main Results: BGF 320 reduced the rate of first occurrence (hazard ratio [95% confidence interval]) of cardiovascular and severe cardiopulmonary events versus GFF, including for time to first cardiovascular adverse event of special interest (0.63 [0.48, 0.82]), cardiac AE (0.60 [0.48, 0.76]), and severe cardiopulmonary event (0.80 [0.67, 0.95]). Conclusions: BGF had a benefit on cardiovascular endpoints and severe cardiopulmonary events versus GFF in patients with moderate to very severe COPD.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Singh, Martinez, Hurst, et al. Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis of a Randomized, Double-Blind, Phase 3 Clinical Trial (ETHOS). Am J Respir Crit Care Med. 2025. PMID: 39213002. doi:10.1164/rccm.202312-2311OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。